Previous 10 | Next 10 |
RedHill's RHB-102 (BEKINDA®) and Opaganib Granted New Patents in Oncology Setting PR Newswire European Patent Office grants RHB-102 patent covering antiemetic extended-release solid dosage forms for the prevention of nausea and vomiting (CINV/RINV), providing protection o...
2023-04-28 07:30:34 ET RedHill press release ( NASDAQ: RDHL ): Q4 GAAP EPS of -$0.12. Revenue of $61.8M (-27.9% Y/Y). For further details see: RedHill GAAP EPS of -$0.12, revenue of $61.8M
RedHill Biopharma Announces Q4/22 & Full-Year 2022 Results and Operational Highlights RedHill Biopharma Announces Q4/22 & Full-Year 2022 Results and Operational Highlights PR Newswire Having extinguished all debt and significantly reduced cost-base, RedHill is now ...
2023-04-11 07:17:29 ET Nasdaq notifies RedHill Biopharma ( NASDAQ: RDHL ) on regaining compliance with the minimum bid price requirement The company maintained a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days, which was achieved o...
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement PR Newswire TEL AVIV, Israel & RALEIGH, N.C. , April 11, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceuti...
RedHill Biopharma Announces Closing of $6 Million Registered Direct Offering PR Newswire TEL AVIV, Israel and RALEIGH, N.C. , April 3, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical c...
2023-03-30 08:20:35 ET RedHill Biopharma ( NASDAQ: RDHL ) entered into a definitive agreement for the purchase and sale of 1.5M ADSs; each ADS represents 400 ordinary shares, series A warrants to purchase up to 1.5M ADSs and series B warrants to purchase up to 1.5M ADSs at a p...
RedHill Biopharma Announces $6 Million Registered Direct Offering PR Newswire TEL AVIV, Israel and RALEIGH, N.C. , March 30, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, to...
RedHill Initiates First Community-Setting Warranty Program to Refund Talicia Non-Responders PR Newswire RedHill commits to reimburse out-of-pocket costs for Talicia patients that complete the full 14-day treatment course and whose infection is not eradicated based on post-...
2023-03-17 02:19:01 ET RedHill Biopharma ( NASDAQ: RDHL ) plans to change the ADS ratio to its non-traded ordinary shares, from one ADS representing ten ordinary shares to one ADS representing four hundred ordinary shares. For the company ...
News, Short Squeeze, Breakout and More Instantly...
Redhill Biopharma Ltd. Company Name:
RDHL Stock Symbol:
NASDAQ Market:
Redhill Biopharma Ltd. Website:
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...
RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040 PR Newswire New Chinese patent notice of allowance issued covering opaganib in combination with immune checkpoint inhibitors (ICIs) as a method of inducing an ...